Article
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation-Associated Advanced Ovarian Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2017
Balasubramaniam Sanjeeve, Beaver Julia A, Horton Sara, Fernandes Laura L, Tang Shenghui, Horne Hisani N, Liu Jinzhong, Liu Chao, Schrieber Sarah J, Yu Jingyu, Song Pengfei, Pierce William, Robertson Kim J, Palmby Todd R, Chiu Haw-Jyh, Lee Eunice Y, Philip Reena, Schuck Robert, Charlab Rosane, Banerjee Anamitro, Chen Xiao Hong, Wang Xing, Goldberg Kirsten B, Sridhara Rajeshwari, Kim Geoffrey, Pazdur Richard
Abstract excerpt
On December 19, 2016, the FDA granted accelerated approval to rucaparib (RUBRACA; Clovis Oncology, Inc.) for the treatment of patients with deleterious BRCA mutation (germline and/or somatic)-associated advanced ovarian cancer who have been treated with two or more chemotherapies. The FDA also approved the FoundationFocus CDx BRCA test (Foundation Medicine, Inc.), the first next-generation sequencing-based...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.